Skip to main content

  • Edwards Sapien M3 Transseptal TMVR System Approved by FDA

    December 23, 2025—Edwards Lifesciences announced FDA approval for the company’s Sapien M3 transcatheter mitral valve replacement (TMVR) system as a transseptal therapy for the treatment of mitral regurgitation (MR).

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Review our Privacy Policy for more details